Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9772076 | 0.99 | HRH2 (0.58) | HRH2HRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL9133749 | 0.86 | HRH3 (0.53) | HRH2HRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL8916883 | 0.84 | HRH2 (0.48) | HRH2HRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL21765955 | 0.81 | KMT2A (0.50) | HRH2HRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL13004090 | 0.81 | ALDH1A1 (0.60) | CYP2D6CYP2C9HIF1ASIGMAR1PRMT6 | |
| SCHEMBL3162705 | 0.80 | SIGMAR1 (0.79) | HRH3SIGMAR1MEN1KMT2AKDM4E | |
| SCHEMBL1883482 | 0.78 | SIGMAR1 (0.77) | HRH3SIGMAR1MEN1KMT2AKDM4E | |
| SCHEMBL29447356 | 0.78 | SIGMAR1 (0.77) | HRH3SIGMAR1MEN1KMT2AKDM4E | |
| SCHEMBL13293358 | 0.77 | ITGB3 (0.61) | HRH2HRH3CYP2D6CYP2C9HIF1A | |
| Hydrochloric Acid SCHEMBL16825187 | 0.77 | SIGMAR1 (0.74) | HRH3SIGMAR1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BenevolentAl Bio Limited (GB) | 2021-08-19 | — | — | US | disclosed |
| WO-2021148805-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2021-07-29 | — | — | WO | disclosed |
| WO-2020039209-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2020-02-27 | — | — | WO | disclosed |
| EP-0288519-A4 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | — | 1992-04-15 | — | — | EP | disclosed |
| US-4965273-A | Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4954507-A | 1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | TNK2, TNIK, TNK1 | HRH2 1289/4885HRH3 2328/4885CYP2D6 1246/4885 |
| US-20210253572-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | MUSK, TPM3, CSNK1A1 | HRH2 1746/4885HRH3 2020/4885CYP2D6 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.